Biggest News Aggregation in the World
๐Ÿ“ฐ Nasdaq Edit News

Page 8 - Nasdaq Edit News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Edit. Real-time updates on events, politics, business and more.

Editas Medicine Announces First Quarter 2021 Results and

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. โ€œOur team is making ...
City Of United Kingdom United States Marks Shearman Mark Shearman Jamesc Mullen

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer May 05, 2021 06:59 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Companyโ€™s Executive Vice President and Chief Scientific Officer. Dr. Shearm...
City Of United Kingdom United States Marks Shearman Jamesc Mullen Genetic Technologies Corporation

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer Cindy Collins to Step Down Effective February 15, 2021 February 08, 2021 08:00 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed C...
United Kingdom James Jimc Mullen Cynthia Cindy Collins Jim Mullen Jamesc Mullen Company Board Of Directors

Editas Medicine Announces Pricing of Offering of Common Stock

Editas Medicine Announces Pricing of Offering of Common Stock January 20, 2021 22:30 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, befor...
New York United States United Kingdom Morgan Stanley Broadridge Financial Solutions Jp Morgan Securities

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science